Drugs Channel
Topics & Medications
Quicklinks
Related Channels

Ruxolitinib Dosage

People who are taking ruxolitinib tablets to treat myelofibrosis should take their dose at the same times each day to keep an even level of the drug in their bloodstream. The specific dosage will vary from person to person, depending on the platelet count, other existing medical conditions, and the person responds to the medicine.

An Introduction to Your Dosage of Ruxolitinib

The dose of ruxolitinib (Jakafi™) your healthcare provider recommends will vary, depending on the following factors:
 
  • Your platelet (a type of blood cell) count
  • How you respond to the medication
  • Other medical conditions you may have
  • Other medications you are taking.
 
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
 

Ruxolitinib Dosing Guidelines

The recommended starting dosage of ruxolitinib for the treatment of myelofibrosis is 15 mg or 20 mg twice daily, depending on your platelet count. Your healthcare provider will get a platelet count, using a simple blood test, before you start treatment to determine your initial dose. If your platelet count is too low, your healthcare provider may recommend waiting to start ruxolitinib until your platelet counts increase.
 
The recommended starting dosage of ruxolitinib is 10 mg twice daily for people who:
 
  • Have moderate or severe kidney disease
  • Have liver disease
  • Are taking certain medications known as CYP 3A4 inhibitors (see Drug Interactions With Ruxolitinib for examples of CYP 3A4 inhibitor medications).
 
The usual starting dose of ruxolitinib for people on kidney dialysis is 15 mg or 20 mg, depending on platelet counts. Doses should be given on days of dialysis, after dialysis is completed.
 
Your dosage may be adjusted based on how you respond to treatment and your platelet counts. Your healthcare provider will get a platelet count every two to four weeks until you are on a stable ruxolitinib dose, and as needed for the remainder of treatment. If your platelet count becomes too low, you may need to take a lower amount or temporarily stop treatment until your platelet count recovers.
 
If you are not adequately responding to treatment after at least four weeks of taking ruxolitinib, your healthcare provider may slowly increase your dosage (usually by 5 mg twice daily). Doses should normally be increased no more often than every two weeks. The maximum recommended dosage is 25 mg twice daily. It is generally recommended that treatment be stopped if your spleen has not reduced in size or your symptoms (such as fatigue) have not improved after six months of treatment.
 
The Zen of Cancer Caregiving - Recharge Your Batteries!

Ruxolitinib Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2018 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.